ALSO NOTED: Procognia, Teva to collaborate; FDA questions Trasylol; and much more...

> In a new collaboration deal, the UK's Procognia will give Teva access to its proprietary glycoanalysis technology as the cooperate on the development of two drug candidates. Teva will fund the work and pay an unspecified set of milestones. Report

> FDA staffers are questioning the deaths and allergic reactions seen in the testing of Bayer's heart surgery drug Trasylol. Report

> The backers of embryonic stem cell research in Michigan have launched a new organization that they hope will eventually overturn a state ban on buying embryonic stem cells from in vitro fertilization clinics. Report

> A scientific consortium led by the University of North Carolina in Chapel Hill will receive a $21.3 million grant to research new drugs for African sleeping sickness (Trypanosomiasis) and Leishmania. Release

> Active Biotech is touting positive results from a Phase I study of a prostate cancer therapy. A Phase II/III study is scheduled for next year. Report

> The FDA has accepted Vernalis' NDA for Frova, a therapy for preventing menstrual migraine. Report

And Finally… A new study shows that Vitamin D can reduce the risk of pancreatic cancer. Article

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.